Array Biopharma Inc.

Brett Joseph Prigaro

Li Ren

David A Moreno

Andrew T Metcalf

James F Blake

Yutong Jiang

Julia Haas

Gabrielle R Kolakowski

Donghua Dai

Dean Russell Kahn

Adam Wade Cook

Ellen Ruth Laird

Erik James Hicken

Bradley Jon Newhouse

Ginelle A Ramann

Spencer Phillip Pajk

Patrick Michael Barbour

Eugene Tarlton

Katie Keaton Brown

Megan L McKenney

Elizabeth A McFaddin

Shane M Walls

Elizabeth A Mcfaddin

Megan L Mckenney

Hailong Zhang

Andrew Terrance Metcalf

David Austin Moreno

Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R, R, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Fused heterocyclic compounds as RET kinase inhibitors

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X, R, R, R, R, Rand Rare as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Compounds for the treatment of BRAF-associated diseases and disorders

Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. 

Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors

Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein Rand Rhave the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. 

Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors

Growing community of inventors

Broomfield, CO, United States of America

Brett Joseph Prigaro